1. Scrip
  2. >>Business
  3. >>Strategy

Bayer, Evotec Alliances Create 'Virtual' Specialized Businesses With Finite Goals

 
• By Lucie Ellis-Taitt

On the sidelines of the BIO-Europe partnering conference, held in Cologne, Germany, Dr Joerg Moeller, head of development for Bayer's pharmaceuticals division, and Evotec CEO Dr Werner Lanthaler tell Scrip why their partnerships work and what challenges they have overcome to create short-term syndicated businesses with specific therapeutic focuses.

Bayer AG and Evotec AG have recently struck a second collaboration, this time in kidney disease, on the back of their successful discovery and development partnership looking at new drug candidates for women's health indications. Bayer's head of development for pharmaceuticals, Dr Joerg Moeller, and Evotec chief, Dr Werner Lanthaler, told Scrip more about their "modern" setup and how fixed project endings help to eradicate development bottlenecks.

In Oct. 2012 Bayer and Evotec entered into a five-year multi-target strategic alliance to identify three small molecule clinical candidates for the treatment of endometriosis. Four years since signing the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.